Summary & Overview
CPT 86413: SARS–CoV–2 Antibody Quantitative Immunoassay
CPT code 86413 represents a quantitative immunoassay to measure antibodies to the SARS–CoV–2 virus in a patient specimen, typically blood. As a clinically focused laboratory code, it captures services that quantify immune response and is relevant for post-infection or post-vaccination assessment. Nationally, demand for SARS–CoV–2 antibody testing has implications for laboratory capacity, payer coverage policies, and clinical interpretation of serology results.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for antibody quantification, typical sites where the service is performed, and the national policy considerations that affect coverage and billing. The publication also reviews common modifiers and reporting practices, reimbursement benchmarks where available, and how this service fits into broader laboratory and infectious disease care pathways.
This summary delivers practical, policy-focused information for laboratory administrators, billing professionals, and payers seeking clarity on CPT code 86413 and its role in SARS–CoV–2 serologic testing.
Billing Code Overview
CPT code 86413 describes a laboratory immunoassay performed by a lab analyst to quantify antibodies to the SARS–CoV–2 virus in a patient specimen, commonly blood. This service is a quantitative serologic antibody test used to measure immune response levels following infection or vaccination.
Service Type: Laboratory — Quantitative immunoassay for SARS–CoV–2 antibodies
Typical Site of Service: Clinical laboratory or hospital laboratory
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult who previously had confirmed or suspected SARS–CoV–2 infection or who received COVID-19 vaccination and presents to an outpatient laboratory or hospital clinical lab for quantitative measurement of anti–SARS–CoV–2 antibodies. The clinician orders the test to assess immune response post-infection or post-vaccination, to evaluate suspected poor serologic response in immunocompromised patients, or to establish baseline antibody level prior to monoclonal antibody therapy or additional vaccine dosing. The workflow includes: specimen collection (usually venous blood), accessioning, performance of an automated or manual immunoassay in the clinical laboratory, result verification by a lab analyst, and reporting of a numeric antibody concentration with interpretive comments to the ordering provider. Typical sites of service are outpatient laboratories, hospital clinical laboratories, and affiliated phlebotomy centers. Patient scenarios commonly include follow-up after COVID-19 illness, assessment of vaccine response in transplant or oncology patients, or pre-therapy antibody screening for eligible monoclonal antibody administration.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard assignment when no other modifier is appropriate |
26 | Professional component | When billing only the professional interpretation or oversight by the laboratory director/pathologist |
TC | Technical component | When billing only the technical component (instrumentation, reagents, technician time) |
90 | Reference (outside) laboratory | When the specimen is sent to an outside reference lab for testing |
52 | Reduced services | When testing is partially reduced due to specimen limitations or truncated processing |
53 | Discontinued procedure | When testing is started but discontinued for legitimate clinical reasons (e.g., invalid specimen) |
59 | Distinct procedural service | When this test is separately identifiable from other services on the same day and documentation supports distinctness |
62 | Two surgeons/dual clinician | Rare for this lab service; use only when two clinicians share responsibility for interpretation according to payer policy |
78 | Unplanned return to the operating/procedure room by the same physician following initial procedure | Not typical; included for completeness when applicable to peri-procedural testing scenarios |
80 | Assistant surgeon | Not typical for this lab service; use only if an assistant clinician has a defined, billable role per payer rules |
90 | Reference laboratory | (Duplicate entry omitted in billing; use single 90 as applicable) |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 208100000X | Clinical Pathology | Laboratory director or clinical pathologist overseeing immunoassay testing |
| 207Q00000X | Medical Laboratory Technologist/Technician | Personnel performing the immunoassay and specimen processing |
| 208000000X | Anatomic and Clinical Pathology | Pathologist who may provide interpretive consultation on serologic results |
| 207L00000X | Clinical Laboratory Personnel | Phlebotomists and lab staff involved in specimen collection and accessioning |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
Z86.16 | Personal history of COVID-19 | Indicates prior SARS–CoV–2 infection prompting antibody quantification |
Z23 | Encounter for immunization | Used when assessing antibody response after COVID-19 vaccination |
D84.9 | Immunodeficiency, unspecified | Representative of immunocompromised patients in whom antibody response assessment is clinically indicated |
T86.10 | Complication of bone marrow transplant, unspecified | Transplant recipients commonly require post-vaccination antibody testing to assess response |
C88.4 | Immunodeficiency with increased susceptibility to infection | Oncology or hematologic conditions where serologic response may be impaired |
U07.1 | COVID-19, virus identified | Recent or ongoing infection where antibody quantification may be part of clinical evaluation |
Z79.899 | Other long-term (current) drug therapy | For patients on immunosuppressive drugs (e.g., corticosteroids) where antibody testing is used to evaluate immune response |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
80053 | Comprehensive metabolic panel | Common concurrent laboratory evaluation for clinical assessment during follow-up of COVID-19 or vaccine-related concerns |
85025 | Complete blood count (CBC) with automated differential | Often ordered alongside immunologic testing to assess overall hematologic status in immunocompromised patients |
86413 | Immunoassay for antibodies to SARS–CoV–2 (quantitative) | Primary procedure described; laboratory immunoassay quantifying anti–SARS–CoV–2 antibodies |
86769 | Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spike protein, quantitative or semiquantitative | Alternative or related code for assays targeting spike protein with quantitative reporting, used in some labs depending on assay target |
86328 | Immunoassay for infectious agent antibody(ies) | General immunoassay code that may be reported for non-specific or older test panels when applicable |
99000 | Handling and/or conveyance of specimen | Facility-specific specimen handling or courier fees when separate and billable per payer policy |